前收盘价格 | 4.44 |
收盘价格 | 4.25 |
成交量 | 27,405 |
平均成交量 (3个月) | 132,082 |
市值 | 1,526,960,256 |
预期市盈率 (P/E Forward) | 59.88 |
价格/销量 (P/S) | 1.63 |
股市价格/股市净资产 (P/B) | 1.41 |
52周波幅 | |
利润日期 | 13 Aug 2025 |
营业毛利率 | -26.26% |
营业利益率 (TTM) | -9.91% |
稀释每股收益 (EPS TTM) | -0.670 |
季度收入增长率 (YOY) | -4.20% |
总债务/股东权益 (D/E MRQ) | 52.48% |
流动比率 (MRQ) | 2.03 |
营业现金流 (OCF TTM) | 34.59 M |
杠杆自由现金流 (LFCF TTM) | -90.11 M |
资产报酬率 (ROA TTM) | -2.42% |
股东权益报酬率 (ROE TTM) | -20.51% |
市场趋势
短期 | 中期 | ||
行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
股票 | Evotec SE | 混合的 | 看跌 |
AIStockmoo 评分
分析师共识 | -2.0 |
内部交易活动 | NA |
价格波动 | -2.0 |
技术平均移动指标 | 0.0 |
技术振荡指标 | 5.0 |
平均 | 0.25 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
部门 | Healthcare |
行业 | Drug Manufacturers - Specialty & Generic |
投资方式 | Small Core |
机构持股比例 | 2.55% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Dcf Advisers, Llc | 31 Mar 2025 | 751,579 |
Fore Capital, Llc | 31 Mar 2025 | 17,005 |
Quadrant Capital Group Llc | 31 Mar 2025 | 5,300 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合